A consistent number of experimental studies have demonstrated the expression of NGF and NGF-receptors in neural crest-derived cells as well as in tumor cell lines from neuroblastoma, lymphoma, glioma, medulloblastoma adrenal tumors and melanoma, suggesting that NGF administration on trkANGFR-bearing cells could lead to cell differentiation and improved prognosis [28–30]. This evidence concerns the gene NGF and lymphoma.